Published online April 2, 2007
PEDIATRICS Vol. 119 No. 4 April 2007, pp. 852-860 (doi:10.1542/peds.2007-0224)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Related Collections
Right arrow Infectious Disease & Immunity

CLINICAL REPORT

Antiviral Therapy and Prophylaxis for Influenza in Children

Committee on Infectious Diseases

Antiviral agents are available that are safe and effective for the treatment and prophylaxis of influenza virus infections in children. The neuraminidase inhibitors (oseltamivir [Tamiflu] and zanamivir [Relenza]) are preferred agents because of current widespread resistance to the adamantanes (amantadine [Symmetrel] and rimantadine [Flumadine]). Therapy should be provided to children with influenza infection who are at high risk of severe infection and to children with moderate-to-severe influenza infection who may benefit from a decrease in the duration of symptoms. Prophylaxis should be provided (1) to high-risk children who have not yet received immunization and during the 2 weeks after immunization, (2) to unimmunized family members and health care professionals with close contact with high-risk unimmunized children or infants who are younger than 6 months, and (3) for control of influenza outbreaks in unimmunized staff and children in an institutional setting. Testing of current H5N1 avian influenza virus isolates, the potential agents of pandemic influenza, suggests susceptibility to oseltamivir and zanamivir. Because no prospective data exist on the efficacy of these agents in humans for H5N1 strains, the dosage and duration of therapy in adults and children may differ from those documented to be effective for epidemic influenza strains.

Key Words: influenza • children • influenza antiviral • oseltamivir • zanamivir • amantadine • rimantadine • ribavirin

Abbreviations: NAI—neuraminidase inhibitor • FDA—Food and Drug Administration • CNS—central nervous system




This article has been cited by other articles:


Home page
 PediatricsHome page
Committee on Infectious Diseases
Prevention of Influenza: Recommendations for Influenza Immunization of Children, 2007-2008
Pediatrics, April 1, 2008; 121(4): e1016 - e1031.
[Abstract] [Full Text] [PDF]

Home page
 AAP NewsHome page
H. H. Bernstein
CDC issues guidance for 2007-'08 flu season
AAP News, September 1, 2007; 28(9): 1 - 2.
[Full Text] [PDF]

Home page
 AAP NewsHome page
Advice on using antivirals for influenza
AAP News, April 1, 2007; 28(4): 8 - 8.
[Full Text] [PDF]